CD8A and neoplasm: Furthermore, the combinations of immunological checkpoint genes expressed in each patient’s CD8+ T cells were distinct, suggesting that immune-modulatory therapies should potentially be targeted to specific individuals based on their tumor checkpoint expression profile (Steele et al., 2020).